These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7571220)

  • 1. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
    Kaplan SA; Meade-D'Alisera P; Quiñones S; Soldo KA
    Urology; 1995 Oct; 46(4):512-7. PubMed ID: 7571220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).
    Guthrie RM; Siegel RL
    Clin Ther; 1999 Oct; 21(10):1732-48. PubMed ID: 10566569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.
    Kirby RS
    Urology; 1995 Aug; 46(2):182-6. PubMed ID: 7542819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group.
    Lepor H; Kaplan SA; Klimberg I; Mobley DF; Fawzy A; Gaffney M; Ice K; Dias N
    J Urol; 1997 Feb; 157(2):525-30. PubMed ID: 8996348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of alpha-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies.
    Kaplan SA; D'Alisera PM
    J Gerontol A Biol Sci Med Sci; 1998 May; 53(3):M201-6. PubMed ID: 9597052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH; Hong SJ; Lee MS
    Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia.
    Kirby RS
    Scand J Urol Nephrol Suppl; 1995; 168():29-33. PubMed ID: 7541549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
    Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
    Kirby RS
    Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.
    Martell N; Luque M;
    J Clin Hypertens (Greenwich); 2001; 3(4):218-23. PubMed ID: 11498652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension.
    Fawzy A; Hendry A; Cook E; Gonzalez F
    Int J Urol; 1999 Jul; 6(7):346-54. PubMed ID: 10445304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical ease of using doxazosin in BPH patients with and without hypertension.
    Steers WD; Kirby RS
    Prostate Cancer Prostatic Dis; 2005; 8(2):152-7. PubMed ID: 15711605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
    Kaplan SA; Soldo KA; Olsson CA
    Eur Urol; 1995; 28(3):223-8. PubMed ID: 8536776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxazosin for benign prostatic hyperplasia in primary care.
    Guthrie R
    Clin Ther; 1997; 19(6):1269-77; discussion 1253-4. PubMed ID: 9444439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
    Mobley DF; Kaplan S; Ice K; Gaffney M; Dias N
    Int J Clin Pract; 1997; 51(5):282-8. PubMed ID: 9489085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of α-blocker 'add on' treatment on blood pressure in symptomatic BPH with or without concomitant hypertension.
    Lee SH; Park KK; Mah SY; Chung BH
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):333-7. PubMed ID: 20567256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of doxazosin in patients with benign prostatic hyperplasia.
    Janknegt RA
    Scand J Urol Nephrol Suppl; 1995; 168():21-7. PubMed ID: 7541548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.